ADXN Addex Therapeutics Ltd Total Debt to Capital

The price trend for Addex Therapeutics (ADXN) shown on this GURU.Markets chart demonstrates a debt-to-equity ratio of 0.04, which correlates with the implementation of environmental and biosafety standards in production. Addex Therapeutics (ADXN) generates revenue by creating unique, patent-protected receptor modulators. The current price is based on the reorganization of operational processes and a focus on priority neurobiological alliances.

This ratio measures the proportion of borrowed funds relative to equity, determining the company's dependence on external financing and its level of financial leverage. By analyzing the total debt-to-equity chart, an investor assesses the stability of Addex Therapeutics (ADXN), whose narrow specialization in neurodegenerative diseases requires a balance between debt load and support from international pharma funds to minimize risks.